Stryker Co. (NYSE:SYK) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 63.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,350 shares of the medical technology company's stock after acquiring an additional 8,687 shares during the period. Tower Research Capital LLC TRC's holdings in Stryker were worth $8,047,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of SYK. Morse Asset Management Inc boosted its stake in Stryker by 16.5% during the third quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company's stock worth $509,000 after buying an additional 200 shares during the last quarter. World Investment Advisors LLC boosted its position in shares of Stryker by 126.1% during the 3rd quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company's stock valued at $2,941,000 after acquiring an additional 4,541 shares during the last quarter. Arvest Bank Trust Division purchased a new stake in shares of Stryker in the third quarter valued at about $245,000. Wilmington Savings Fund Society FSB increased its position in Stryker by 13.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company's stock worth $16,183,000 after purchasing an additional 5,361 shares during the last quarter. Finally, Tidal Investments LLC raised its stake in Stryker by 13.9% during the third quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company's stock worth $6,314,000 after purchasing an additional 2,139 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on SYK shares. Citigroup restated a "buy" rating and set a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Wells Fargo & Company boosted their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Finally, The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Stock Up 1.1 %

Shares of NYSE:SYK traded up $3.83 during trading hours on Thursday, reaching $360.94. The stock had a trading volume of 1,349,722 shares, compared to its average volume of 1,357,113. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm's 50 day moving average is $368.69 and its 200-day moving average is $372.95. The stock has a market capitalization of $137.77 billion, a price-to-earnings ratio of 46.51, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm earned $3.46 EPS. Research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio (DPR) is 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.